Institute for the Study of Urological Diseases, Greece
13
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
PRP Exosomes Therapy for Erectile Dysfunction
Role: lead
Repeating LiST for Refractory Non-bacterial Prostatitis/Pelvic Pain Syndrome
Role: lead
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
Role: lead
The Effect of Three Endourological Procedures for the Management of Renal Calculi Regarding Acute Kidney Injury
Role: lead
Low-intensity Shockwaves Therapy for the Treatment of Patients With Moderate Vasculogenic Erectile Dysfunction
Role: lead
Low-intensity Shockwaves Therapy + Tadalafil 5mg for the Treatment of Severe Erectile Dysfunction
Role: lead
Low-intensity Shockwave Therapy (LiST) for the Treatment of Mild and Mild-to-moderate Vasculogenic Erectile Dysfunction
Role: lead
The Ideal LiST Session Frequency Protocol for CPPS Treatment
Role: lead
Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function
Role: lead
Low-intensity Shockwave Therapy for Non-bacterial Prostatitis/Pelvic Pain Syndrome
Role: lead
Low Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: Standardisation of Treatment Protocol
Role: lead
6 vs 12 Sessions in Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED)
Role: lead
Effect of Repeating Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED)
Role: lead
All 13 trials loaded